Liver cancer · 2026
Carvedilol versus Propranolol in Patients with Hepatocellular Carcinoma: A Nationwide Cohort Study.
СтатьяНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Song Byeong Geun, Lee Myeongcheol, Cho Juhee, Gwak Geum-Youn, Kang Danbee, Sinn Dong Hyun
Аннотация
INTRODUCTION: Beta-blockers reduce portal hypertension; however, evidence comparing carvedilol and propranolol in patients with hepatocellular carcinoma (HCC) is lacking. We aimed to compare the clinical outcomes of carvedilol versus propranolol in patients with HCC.
METHODS: Using the Korean National Health Insurance Service database (2009-2023), we identified 11,124 patients with newly diagnosed HCC who were prescribed either carvedilol (n = 2,457) or propranolol (n = 8,667) within 180 days of diagnosis. The primary outcome was all-cause mortality, and the secondary outcome was hepatic decompensation. Multivariable Cox regression and 1:2 PS matching were used as primary analytical approaches, with sensitivity analyses restricted to 6-month survivors and a new-user design.
RESULTS: During a median follow-up of 1.5 years, carvedilol use was associated with a significantly lower risk of hepatic decompensation (adjusted hazard ratio [aHR] 0.67; 95% confidence interval [CI] 0.62-0.72) and all-cause mortality (aHR 0.84; 95% CI 0.79-0.90) compared to propranolol. In the 1:2 PS-matched cohort (n = 5,922), these associations remained consistent for both decompensation (HR 0.68; 95% CI 0.63-0.74) and mortality (HR 0.84; 95% CI 0.78-0.90). These benefits were consistent across various subgroups, and in sensitivity analysis excluding early death within 6 months from diagnosis and using a new-user design.
CONCLUSION: In patients with HCC, carvedilol was associated with better survival and lower risk of hepatic decompensation than propranolol. Carvedilol may be the preferred beta-blocker over propranolol in the setting of HCC.
METHODS: Using the Korean National Health Insurance Service database (2009-2023), we identified 11,124 patients with newly diagnosed HCC who were prescribed either carvedilol (n = 2,457) or propranolol (n = 8,667) within 180 days of diagnosis. The primary outcome was all-cause mortality, and the secondary outcome was hepatic decompensation. Multivariable Cox regression and 1:2 PS matching were used as primary analytical approaches, with sensitivity analyses restricted to 6-month survivors and a new-user design.
RESULTS: During a median follow-up of 1.5 years, carvedilol use was associated with a significantly lower risk of hepatic decompensation (adjusted hazard ratio [aHR] 0.67; 95% confidence interval [CI] 0.62-0.72) and all-cause mortality (aHR 0.84; 95% CI 0.79-0.90) compared to propranolol. In the 1:2 PS-matched cohort (n = 5,922), these associations remained consistent for both decompensation (HR 0.68; 95% CI 0.63-0.74) and mortality (HR 0.84; 95% CI 0.78-0.90). These benefits were consistent across various subgroups, and in sensitivity analysis excluding early death within 6 months from diagnosis and using a new-user design.
CONCLUSION: In patients with HCC, carvedilol was associated with better survival and lower risk of hepatic decompensation than propranolol. Carvedilol may be the preferred beta-blocker over propranolol in the setting of HCC.